Related references
Note: Only part of the references are listed.SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1
Aleksandra Novikov et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis
Xiaoling Cai et al.
OBESITY (2018)
US Renal Data System 2017 Annual Data Report Epidemiology of Kidney Disease in the United States
Rajiv Saran et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
Brendon L. Neuen et al.
CIRCULATION (2018)
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Merlin C. Thomas et al.
DIABETOLOGIA (2018)
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
Chiara Ghezzi et al.
DIABETOLOGIA (2018)
Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study
Giuseppe Penno et al.
DIABETOLOGIA (2018)
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Hiddo J. L. Heerspink et al.
KIDNEY INTERNATIONAL (2018)
Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice
Shinji Tanaka et al.
KIDNEY INTERNATIONAL (2018)
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
David Z. I. Cherney et al.
KIDNEY INTERNATIONAL (2018)
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease
Claire C. J. Dekkers et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection
Hiroyuki Umino et al.
SCIENTIFIC REPORTS (2018)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
Eugene Han et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Christoph Wanner et al.
CIRCULATION (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study
Harindra Rajasekeran et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia
Stephen E. Sherman et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy
Paola Cassis et al.
JCI INSIGHT (2018)
Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study
Zhong Yuan et al.
DIABETES OBESITY & METABOLISM (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
Hiddo J. L. Heerspink et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE
Xiaoxin X. Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits
Jens Oellgaard et al.
KIDNEY INTERNATIONAL (2017)
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Adeera Levin et al.
LANCET (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients
Mohsen Mazidi et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z. I. Cherney et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Meg J. Jardine et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis
Girish N. Nadkarni et al.
DIABETES CARE (2017)
Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes
Anna Solini et al.
DIABETES OBESITY & METABOLISM (2017)
Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects
Luke Norton et al.
DIABETES OBESITY & METABOLISM (2017)
Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES CARE (2017)
Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease
Qiuyue Ma et al.
PHYSIOLOGICAL REPORTS (2017)
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Hiddo J. L. Heerspink et al.
CIRCULATION (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
Paola Fioretto et al.
DIABETOLOGIA (2016)
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
Peter Gde et al.
DIABETOLOGIA (2016)
Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
Maryam Afkarian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
Yanling Zhang et al.
PLOS ONE (2016)
Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
Seok Joon Shin et al.
PLOS ONE (2016)
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
Linda A. Gallo et al.
SCIENTIFIC REPORTS (2016)
Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice
Takashi Hatanaka et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Understanding EMPA-REG OUTCOME
Marcel H. A. Muskiet et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Hiddo J. Lambers Heerspink et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Acute SGLT inhibition normalizes O-2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats
Julie O'Neill et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition
Anita T. Layton et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats
Naoki Kojima et al.
PHYSIOLOGICAL REPORTS (2015)
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
Yuliya Lytvyn et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
Marko Skrtic et al.
DIABETOLOGIA (2014)
Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport
M. A. Abdul-Ghani et al.
JOURNAL OF INTERNAL MEDICINE (2014)
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
David Z. I. Cherney et al.
KIDNEY INTERNATIONAL (2014)
Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
Muralikrishna Gangadharan Komala et al.
PLOS ONE (2014)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes
Kazuhiro Hasegawa et al.
NATURE MEDICINE (2013)
Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
Tadahiro Shimazu et al.
SCIENCE (2013)
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2013)
Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats
Naoki Kojima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Early Renal Function Decline in Type 2 Diabetes
Meda E. Pavkov et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease
Jan Skupien et al.
KIDNEY INTERNATIONAL (2012)
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Volker Vallon et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
Frank A. Holtkamp et al.
KIDNEY INTERNATIONAL (2011)
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
Hermann Haller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Stretch reduces nephrin expression via an angiotensin II-AT1-dependent mechanism in human podocytes: effect of rosiglitazone
Ilaria Miceli et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2010)
Solute carrier family 2, member 9 and uric acid homeostasis
Chris Cheeseman
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2009)
Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes.
Michael Mauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effect of a multifactorial intervention on mortality in type 2 diabetes
Peter Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Anaemia in diabetes: is there a rationale to TREAT?
MC Thomas et al.
DIABETOLOGIA (2006)
The MCP-1/CCR2 system has direct proinflammatory effects in human mesangial cells
S Giunti et al.
KIDNEY INTERNATIONAL (2006)
Preventing microalbuminuria in type 2 diabetes
P Ruggenenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Activation of a local tissue angiotensin system in podocytes by mechanical strain
RV Durvasula et al.
KIDNEY INTERNATIONAL (2004)
GLUT-1 overexpression - Link between hemodynamic and metabolic factors in glomerular injury?
L Gnudi et al.
HYPERTENSION (2003)
Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
AI Adler et al.
KIDNEY INTERNATIONAL (2003)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Mechanical stretch-induced fibronectin and transforming growth factor-β1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent
G Gruden et al.
DIABETES (2000)
Share Paper
